OPEN END TURBO OHNE STOP-LOSS - EVOTEC Share Price

Certificat

DE000LX1KDA8

Market Closed - Börse Stuttgart 09:39:20 31/05/2024 pm IST
2.62 EUR -0.76% Intraday chart for OPEN END TURBO OHNE STOP-LOSS - EVOTEC
Current month+3.97%
1 month+3.97%
Date Price Change
31/24/31 2.62 -0.76%
30/24/30 2.64 +0.38%
29/24/29 2.63 +2.33%
28/24/28 2.57 -.--%
27/24/27 2.57 -1.15%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 09:39 pm IST

More quotes

Static data

Product typeKnock-Out ohne Stop Loss
Buy / SellPUT
Underlying EVOTEC SE
Issuer Lang & Schwarz
WKN LX1KDA
ISINDE000LX1KDA8
Date issued 10/02/2022
Strike 33.93
Maturity Unlimited
Parity 10 : 1
Emission price 0.68
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 2.64
Lowest since issue 0.67

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.655 EUR
Average target price
20.79 EUR
Spread / Average Target
+140.21%
Consensus